Achievement of the Full-Year Consolidated Earnings Forecast for the Fiscal Year Ended December 2021
First written in FY2021-Q2. 1 of 3 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2020: 3 of 22 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2021AdvancedAnnual report
「Revenue for fiscal 2021 was affected to some extent by the spread of COVID-19 in the nutraceuticals-related business and other areas, in addition to the significant revenue decline resulting from the expiration of the Sprycel and Keppra contracts, but progressed in line with plan at 99.9% of the plan.」
Against the full-year earnings forecast for the fiscal year ending December 2021, revenue progressed in line with plan at 99.9% of the plan. - FY2021-Q3RestatedAnnual report
「As described above, we anticipate a wide range of effects from the spread of COVID-19 on the Group's businesses. Having fully recognized management risks in advance, we will take comprehensive measures for each risk and work to enhance corporate value and achieve the full-year consolidated earnings forecast for the fiscal year ending December 2021.」
The policy of taking measures to address anticipated effects of the spread of COVID-19 on sales, production and R&D and aiming to achieve the full-year consolidated earnings forecast for the fiscal year ending December 2021 continues. - FY2021-Q2First statedAnnual report
「As described above, we anticipate a wide range of effects from the spread of COVID-19 on the Group's businesses. Having fully recognized management risks in advance, we will take comprehensive measures for each risk, seek to enhance corporate value, and work to achieve the full-year consolidated earnings forecast for the fiscal year ending December 2021.」
For the first time, the Company explicitly stated that it aims to achieve the full-year consolidated earnings forecast for the fiscal year ending December 2021 while responding to the spread of COVID-19.